Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.8 USD | -6.63% | -14.61% | -59.18% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 334M |
---|---|---|---|---|---|
Net income 2024 * | -46M | Net income 2025 * | -72M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.67
x | P/E ratio 2025 * |
-4.37
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.86% |
Latest transcript on Anavex Life Sciences Corp.
1 day | -6.63% | ||
1 week | -14.61% | ||
Current month | -25.34% | ||
1 month | -21.16% | ||
3 months | -36.77% | ||
6 months | -32.74% | ||
Current year | -59.18% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Sandra Boenisch
DFI | Director of Finance/CFO | 43 | 15-09-30 |
Edward Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Tom Skarpelos
FOU | Founder | 57 | 04-01-22 |
Jiong Ma
CHM | Chairman | 60 | 21-05-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.07% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 3.8 | -6.63% | 1,654,479 |
24-04-17 | 4.07 | -1.21% | 1,337,487 |
24-04-16 | 4.12 | -2.60% | 1,252,081 |
24-04-15 | 4.23 | -1.51% | 1,089,915 |
24-04-12 | 4.295 | -3.48% | 1,127,643 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-59.18% | 334M | |
-3.30% | 102B | |
+1.79% | 96.84B | |
-0.44% | 21.48B | |
-18.35% | 20.82B | |
-7.45% | 18.6B | |
-40.31% | 16.81B | |
-26.84% | 13.78B | |
+0.59% | 13.4B | |
+20.86% | 11.06B |
- Stock Market
- Equities
- AVXL Stock